Nuvalent, Inc. (NUVL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$123.960.00%
Close 2026-07-16 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Nuvalent is advancing with a $10.6 billion acquisition by GSK. The deal shows strong confidence in its cancer drug pipeline. Nuvalent has beaten earnings estimates recently. It holds about $1.4 billion in cash to fund operations.
Nuvalent is still losing money with rising operating losses. It missed earnings in late 2025. Revenue is very low and expected to stay small next year. The company depends on successful drug development and approval.
The price is about 0% below our fair value near $124. The market expects no revenue growth and continued losses. Our view aligns with Street targets but sees risk in execution.
Breaks if: Merger fails or key drug trials show negative results
Breaks if: Annual revenue stays below $10 million in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is cautious due to the company's loss-making status and management volatility, despite a recent merger with GlaxoSmithKline.
The market appears to have low expectations for NUVL, as indicated by the low fragility tier. There is a recognition of the company's challenges, particularly its operating losses, which are already priced into the stock.
Fundamentals are likely to remain under pressure in the near term, with increasing operating losses and cash burn. Management's focus on completing the merger with GSK may provide some stability, but the overall financial performance has been neutral.
The thesis hinges on external factors such as the performance of sector bellwethers like VRTX and REGN, which could influence NUVL's trajectory. Additionally, the potential impact of a weakening jobs report on the healthcare sector could pose risks.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Operating losses worsen beyond -$120M per quarter over next year
Nuvalent is managing significant operating losses, with a focus on reducing them over time.
Over the next 1 to 3 years, NUVL's performance will depend on its ability to manage losses and leverage the merger effectively. Not investment advice.